RxDoctor Payments Data

Howard Edelstein, MD

Infectious Disease · Oakland, CANPI 1497765069

Payments from drug & device makers

$100,259in general payments, 2019–2025

Across 46 payments — averaging $2179.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$52K
  • Viiv Healthcare Company$48K
  • Pfizer$34

What the payments were for

  • Consulting fees$22,85097%
  • Food & beverage$7093%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead20$52,220
Viiv Healthcare Company24$48,005
Pfizer2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,259 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$103,560
Medicare patients
133
Services billed
1,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala44$201,652
TivicayDolutegravir Sodium65$178,056
PrezcobixDarunavir/Cobicistat29$97,751
TriumeqAbacavir/Dolutegravir/Lamivudi22$94,369
DescovyEmtricitabine/Tenofov Alafenam39$92,707
OdefseyEmtricitab/Rilpiviri/Tenof Ala20$79,997
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$48,731
MounjaroTirzepatide21$30,376
JardianceEmpagliflozin17$27,753
TrulicityDulaglutide25$27,208
EliquisApixaban20$23,805
EdurantRilpivirine Hcl14$23,203
Nevirapine ErNevirapine26$4,251
Testosterone11$3,644
Atorvastatin Calcium196$2,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$52,220$294,36083 claims
Viiv Healthcare CompanyTivicay, Triumeq$48,005$272,42587 claims
PfizerEliquis$34$23,80520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 856 infectious disease providers in California.

Other infectious disease in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →